Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Progesterone for Stress Reactivity and Cannabis Use
NCT03729869Phase 2Completed
- Sponsor
- Medical University of South Carolina
- Start
- Jan 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of progesterone in cannabis use disorder (CUD), sponsored by Medical University of South Carolina. Primary endpoint: Cannabis Craving at 1 week. Started Jan 2019; status: completed.
02
Drugs
progesterone
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT03729869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729869.